The anticancer effect of the <scp>HDAC</scp> inhibitor belinostat is enhanced by inhibitors of Bcl‐ <scp> x <sub>L</sub> </scp> or Mcl‐1 in ovarian cancerCécilia Thomine(Inserm), Marie Villedieu(Cancers et Préventions)Molecular OncologyJune 8, 202510.1002/1878-0261.70050Cited by 3SaveCiteExport RISWatch citationsRelated PapersAcquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment|Gynecologic Oncology|2006|53